Key Points: Rybelsus (oral semaglutide) is often a great fit for those who prefer a daily pill over weekly injections
Congressional Policy Considerations As the use of GLP-1 drugs expands beyond diabetes management to cardiovascular and obesity treatment, the associated costs and coverage policies likely will continue to be a focal point facing policymakers
Semaglutide is just one part of that equation
The study will be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (26 October), by Dr Thomas Karagiannis, Aristotle University of Thessaloniki, Thessaloniki, Greece, and colleagues
The clinic educates patients on how it works and may review medically supervised alternatives such as Tesamorelin
doi: 10.1177/1932296814525188